A decades-old pill called TOFA helped obese mice burn fat fast without eating less or losing muscle, according to new reports.
Story Snapshot
- Obese male mice lost about 18% of body weight in four weeks with oral TOFA, with no drop in food intake.
- Energy use rose by up to 18% without more activity or higher body temperature.
- Fat mass fell while lean mass was largely preserved in treated mice.
- Findings were published in Science Advances and linked to a University of California, Berkeley team.
A mouse study reports weight loss without hunger or muscle loss
University of California, Berkeley researchers tested TOFA in obese mice and saw quick fat loss with steady eating. Male mice given oral TOFA lost about 18% of body weight over four weeks.
Food intake did not change during treatment, which points to a mechanism beyond appetite control. Reports say most of the lost weight was fat, while lean mass stayed about the same. The journal Science Advances published the work with a traceable record, including a dated article identifier.
The core claim hinges on energy burn, not dieting. Metabolic cage data reported by coverage show energy use rose by as much as 18% in treated mice.
The animals did not move more and did not run hotter, which suggests a shift in how cells use fuel rather than a simple behavior change.
That matters because many weight-loss drugs rely on eating less, which can strip muscle along with fat. TOFA’s profile reads more like a fuel switch than a hunger switch.
Researchers identified an oral compound that helped obese male mice lose 18% of their body weight without suppressing appetite or reducing lean muscle.
Known as TOFA, the molecule blocks new fat production and prompts cells to burn existing fat. Combined with semaglutide or… pic.twitter.com/LKF01ziXME
— Fox News Health (@foxnewshealth) September 2, 2026
The mechanism: block fat-making, nudge fat-burning
Reports describe a two-part action that fits known metabolic logic. First, TOFA appears to inhibit enzymes that build fatty acids and other lipids. That cuts the body’s ability to store extra energy as fat.
Second, it seems to trigger pathways that tell cells to burn more fat and spend more energy. Coverage links this to energy-sensing signals in liver and muscle that raise fat oxidation. This dual push-pull could explain the higher energy use with stable appetite.
Lean mass preservation stands out in a market that worries about muscle loss. Appetite-suppressing drugs often reduce both fat and lean tissue to some degree. That can be acceptable or even expected during weight loss.
Yet, for older adults, keeping muscle matters for balance, strength, and independence. The reports on this study say TOFA-treated mice cut fat while keeping lean mass about steady, which frames it as a possible add-on or alternative approach.
Where TOFA might fit next to GLP-1 drugs
Glucagon-like peptide-1 drugs have set a high bar for weight loss, but muscle loss debates linger. Reviews show most of the lost weight with these drugs is fat, and the share of lean loss is not out of line with diet-only plans.
Even so, many doctors now pair strength training and protein targets with these medicines to protect muscle. A drug that raises energy use and preserves lean mass could pair with or complement these regimens in future studies, if results translate beyond mice.
Some reports mention combining TOFA with popular incretin drugs in animals. They suggest additive or stronger effects on weight and fat markers. The details on interaction testing are not public in the summaries.
If future data confirm clean add-on benefits without muscle trade-offs, that would appeal to patients who already tolerate incretin drugs but want less plateau and more function. That is a common-sense goal that aligns with better healthspan, not just a smaller number on the scale.
What the numbers do and do not tell us yet
The public record shows clear, repeatable headlines: stable food intake, higher energy burn, fat loss, and preserved lean mass in obese male mice. Those are strong signals for a preclinical story.
The paper’s publication and University of California, Berkeley ties give a traceable line of work. The coverage does not list sample sizes, blinding, or exact methods in depth. That level of detail will guide how teams design the next wave of tests and confirm how lean mass was measured.
TOFA Anti-Fat Compound.
A team of researchers has identified a decades-old oral compound that attacks obesity through a completely different approach, burning more energy from within cells rather than simply telling the brain to eat less.
Published in the journal Science… pic.twitter.com/PiMK0emY7E
— Brian Roemmele (@BrianRoemmele) August 28, 2026
The take-home for readers who track fitness and aging is simple. The best weight loss keeps muscle and burns fat. This study’s reports point to that target, using an old compound with a new angle.
If future trials show similar effects in females, other species, and people, the market will notice. If not, the field still gains a sharper map of how to turn up energy burn safely. For now, the claims square with the facts presented, and the door to better options just opened a notch.
Sources:
foxnews.com, particle.news, cen.acs.org, vcresearch.berkeley.edu
